HighTower Advisors LLC Sells 748 Shares of Charles River Laboratories International, Inc. $CRL

HighTower Advisors LLC trimmed its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 11.1% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 5,965 shares of the medical research company’s stock after selling 748 shares during the quarter. HighTower Advisors LLC’s holdings in Charles River Laboratories International were worth $898,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the business. Invesco Ltd. increased its position in Charles River Laboratories International by 7.2% during the first quarter. Invesco Ltd. now owns 1,108,358 shares of the medical research company’s stock worth $166,830,000 after acquiring an additional 74,178 shares during the period. Ariel Investments LLC grew its stake in Charles River Laboratories International by 18.9% during the fourth quarter. Ariel Investments LLC now owns 1,067,327 shares of the medical research company’s stock worth $197,029,000 after buying an additional 169,640 shares in the last quarter. Mackenzie Financial Corp grew its stake in Charles River Laboratories International by 2.6% during the first quarter. Mackenzie Financial Corp now owns 1,002,951 shares of the medical research company’s stock worth $150,964,000 after buying an additional 25,878 shares in the last quarter. Charles Schwab Investment Management Inc. grew its stake in Charles River Laboratories International by 4.4% during the first quarter. Charles Schwab Investment Management Inc. now owns 577,322 shares of the medical research company’s stock worth $86,899,000 after buying an additional 24,347 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its stake in Charles River Laboratories International by 1,721.1% during the first quarter. Assenagon Asset Management S.A. now owns 570,097 shares of the medical research company’s stock worth $85,811,000 after buying an additional 538,792 shares in the last quarter. 98.91% of the stock is owned by institutional investors.

Charles River Laboratories International Trading Down 0.6%

CRL opened at $162.66 on Thursday. The company’s 50 day moving average is $158.64 and its 200-day moving average is $148.73. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $230.02. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The company has a market cap of $8.00 billion, a P/E ratio of -122.30, a PEG ratio of 5.22 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, topping the consensus estimate of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The business had revenue of $1.03 billion for the quarter, compared to the consensus estimate of $983.76 million. During the same period last year, the company earned $2.80 EPS. The firm’s revenue was up .6% compared to the same quarter last year. Equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 800 shares of Charles River Laboratories International stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. This trade represents a 3.21% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Barclays increased their price objective on shares of Charles River Laboratories International from $155.00 to $165.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 7th. Robert W. Baird increased their price objective on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a “neutral” rating in a research note on Thursday, May 8th. Citigroup upgraded shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $150.00 to $200.00 in a research note on Wednesday, July 9th. Evercore ISI increased their price objective on shares of Charles River Laboratories International from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. Finally, Wall Street Zen downgraded shares of Charles River Laboratories International from a “strong-buy” rating to a “buy” rating in a research note on Sunday, August 17th. Five investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $175.69.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).